Anna Nijdam Sells 2,670 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total value of $82,422.90. Following the completion of the sale, the insider directly owned 46,275 shares of the company’s stock, valued at $1,428,509.25. The trade was a 5.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The stock was sold at an average price of $30.60, for a total value of $55,967.40.
• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The stock was sold at an average price of $30.74, for a total value of $169,100.74.

Pharvaris Price Performance

PHVS opened at $31.60 on Wednesday. Pharvaris N.V. has a 12 month low of $16.00 and a 12 month high of $33.33. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -9.94 and a beta of -2.35. The business has a fifty day moving average price of $29.40 and a 200 day moving average price of $27.42.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, research analysts anticipate that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP lifted its stake in Pharvaris by 472.3% in the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after buying an additional 261,355 shares in the last quarter. DV Trading LLC purchased a new stake in Pharvaris in the 1st quarter valued at approximately $4,067,000. Stempoint Capital LP lifted its stake in Pharvaris by 48.4% in the 1st quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after buying an additional 28,248 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Pharvaris by 23.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after buying an additional 20,000 shares in the last quarter. Finally, Amundi lifted its stake in Pharvaris by 12.0% in the 1st quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after buying an additional 3,312 shares in the last quarter.

Analysts Set New Price Targets

PHVS has been the subject of several analyst reports. Wedbush upped their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. UBS Group set a $74.00 price objective on Pharvaris in a research note on Wednesday, May 13th. Wolfe Research initiated coverage on Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Royal Bank Of Canada reduced their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.